Light-chain (AL) amyloidosis · 14 regimens
Cost vs Efficacy · 5 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Daratumumab monotherapy Variant #01 | — | R 84 235 | 28d | — | — | ~13 | ~R 1 095 049 PFS proxy · indirect | 1 |
Thalidomide and Dexamethasone (TD) Variant #06 | — | R 64 543 | 30d | ~18.6 mo | ~63.2 mo | ~18 | ~R 678 160 PFS proxy · indirect | 3 |
Ixazomib monotherapy Variant #01 | — | R 39 177 | 28d | ~22.0 mo | — | ~12 | ~R 470 130 PFS proxy · indirect | 2 |
Ixazomib and Dexamethasone Variant #01 | — | R 33 351 | 28d | — | — | ~2 | ~R 66 702 indirect | — |
Pomalidomide and Dexamethasone (Pd) Variant #01 | — | R 29 040 | 28d | ~6.5 mo | ~17.4 mo | ~2 | ~R 58 079 PFS proxy · indirect | 13 |
CTD Variant #01 | — | R 19 552 | 21d | — | — | ~10 | ~R 86 855 indirect | — |
Bendamustine and Dexamethasone Variant #01 | — | R 7 431 | 28d | — | — | ~6 | ~R 44 587 indirect | — |
Bortezomib monotherapy Variant #03 | — | R 6 762 | 21d | ~30.3 mo | — | ~8 | ~R 54 096 PFS proxy · indirect | 5 |
Lenalidomide and Dexamethasone (RD) Variant #02 | — | R 5 879 | 28d | — | — | ~13 | ~R 76 427 indirect | — |
Lenalidomide and Dexamethasone (Rd) Variant #02 | — | R 4 309 | 28d | ~21.0 mo | ~55.4 mo | ~40 | ~R 132 764 PFS proxy · indirect | 27 |
CRd Variant #03 | — | R 3 754 | 28d | — | — | ~12 | ~R 45 051 indirect | — |
Cyclophosphamide and Dexamethasone Variant #01 | — | R 1 411 | 28d | — | ~10.0 mo | ~2 | ~R 2 822 PFS proxy · indirect | 1 |
Dexamethasone monotherapy Variant #03 | — | R 1 215 | 28d | — | — | ~4 | ~R 4 861 indirect | — |
Melphalan and Dexamethasone Variant #05 | — | R 433 | 42d | — | ~45.5 mo | ~19 | ~R 8 232 PFS proxy · indirect | 2 |
14 of 14 regimens shown